Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (3248)
All Articles published online
|
Dec 28, 2005 (publication date) through Nov 30, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Sookoian S, Fernández MA, Castaño G. Effects of six months losartan administration on liver fibrosis in chronic hepatitis C patients: A pilot study. World J Gastroenterol 2005; 11(48): 7560-7563 [PMID: 16437678 DOI: 10.3748/wjg.v11.i48.7560] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v11/i48/7560.htm |
| Number | Citing Articles |
| 1 |
Josephine A. Grace, Chandana B. Herath, Kai Yan Mak, Louise M. Burrell, Peter W. Angus. Update on new aspects of the renin–angiotensin system in liver disease: clinical implications and new therapeutic options. Clinical Science 2012; 123(4): 225 doi: 10.1042/CS20120030
|
| 2 |
Patricio Ibañez, Nancy Solis, Margarita Pizarro, Gloria Aguayo, Ignacio Duarte, Juan Francisco Miquel, Luigi Accatino, Marco Arrese. Effect of losartan on early liver fibrosis development in a rat model of nonalcoholic steatohepatitis. Journal of Gastroenterology and Hepatology 2007; 22(6): 846 doi: 10.1111/j.1440-1746.2006.04700.x
|
| 3 |
Hyun Ho Yun, Sunyoung Park, Myung-Jin Chung, Ji-Yoon Son, Jae-Min Park, Seung-Jun Jung, Jae-Hyuk Yim, Kyung-Ku Kang, Seongrim Byeon, Su-Min Baek, Seoung-Woo Lee, A-Rang Lee, Tae-Hwan Kim, Jin-Kyu Park, Kyu-Shik Jeong. Effects of losartan and l-serine in a mouse liver fibrosis model. Life Sciences 2021; 278: 119578 doi: 10.1016/j.lfs.2021.119578
|
| 4 |
Yong-Han Paik, Jonghwa Kim, Tomonori Aoyama, Samuele De Minicis, Ramon Bataller, David A. Brenner. Role of NADPH Oxidases in Liver Fibrosis. Antioxidants & Redox Signaling 2014; 20(17): 2854 doi: 10.1089/ars.2013.5619
|
| 5 |
Erica Novo, Fabio Marra, Maurizio Parola. Studies on Hepatic Disorders. Oxidative Stress in Applied Basic Research and Clinical Practice 2015; : 171 doi: 10.1007/978-3-319-15539-5_8
|
| 6 |
O. Guillaud, K.C. Gurram, M. Puglia, L. Lilly, O. Adeyi, E.L. Renner, N. Selzner. Angiotensin Blockade Does Not Affect Fibrosis Progression in Recurrent Hepatitis C After Liver Transplantation. Transplantation Proceedings 2013; 45(6): 2331 doi: 10.1016/j.transproceed.2013.01.067
|
| 7 |
Amanda M Murphy, Alison L Wong, Michael Bezuhly. Modulation of angiotensin II signaling in the prevention of fibrosis. Fibrogenesis & Tissue Repair 2015; 8(1) doi: 10.1186/s13069-015-0023-z
|
| 8 |
Jingjing Zhao, Hao Yang, Bo Chen, Rui Zhang. The skeletal renin-angiotensin system: A potential therapeutic target for the treatment of osteoarticular diseases. International Immunopharmacology 2019; 72: 258 doi: 10.1016/j.intimp.2019.04.023
|
| 9 |
Ki Tae Suk, Moon Young Kim, Dong Hun Park, Kyu Hong Kim, Ki Won Jo, Jin Hon Hong, Jae Woo Kim, Hyun Soo Kim, Sang Ok Kwon, Soon Koo Baik. Effect of Propranolol on Portal Pressure and Systemic Hemodynamics in Patients with Liver Cirrhosis and Portal Hypertension: A Prospective Study. Gut and Liver 2007; 1(2): 159 doi: 10.5009/gnl.2007.1.2.159
|
| 10 |
Sadashiva S. Karnik, Hamiyet Unal, Jacqueline R. Kemp, Kalyan C. Tirupula, Satoru Eguchi, Patrick M. L. Vanderheyden, Walter G. Thomas, Eliot H. Ohlstein. International Union of Basic and Clinical Pharmacology. XCIX. Angiotensin Receptors: Interpreters of Pathophysiological Angiotensinergic Stimuli. Pharmacological Reviews 2015; 67(4): 754 doi: 10.1124/pr.114.010454
|
| 11 |
Shuvra Ray, Carlo De Salvo, Theresa T. Pizarro. Central role of IL-17/Th17 immune responses and the gut microbiota in the pathogenesis of intestinal fibrosis. Current Opinion in Gastroenterology 2014; 30(6): 531 doi: 10.1097/MOG.0000000000000119
|
| 12 |
Adriana L. Burgueño, Tomas F. Gianotti, Noelia G. Mansilla, Carlos J. Pirola, Silvia Sookoian. Cardiovascular disease is associated with high-fat-diet-induced liver damage and up-regulation of the hepatic expression of hypoxia-inducible factor 1α in a rat model. Clinical Science 2013; 124(1): 53 doi: 10.1042/CS20120151
|
| 13 |
Mary S. McGrath, Brian J. Wentworth. The Renin–Angiotensin System in Liver Disease. International Journal of Molecular Sciences 2024; 25(11): 5807 doi: 10.3390/ijms25115807
|
| 14 |
Paschalis Paschos, Konstantinos Tziomalos. Nonalcoholic fatty liver disease and the renin-angiotensin system: Implications for treatment. World Journal of Hepatology 2012; 4(12): 327-331 doi: 10.4254/wjh.v4.i12.327
|
| 15 |
Tarek M. Mostafa, Gamal A. El-azab, Gamal A. Badra, Alyaa S. Abdelwahed, Abeer A. Elsayed. Effect of Candesartan and Ramipril on Liver Fibrosis in Patients with Chronic Hepatitis C Viral Infection: A Randomized Controlled Prospective Study. Current Therapeutic Research 2021; 95: 100654 doi: 10.1016/j.curtheres.2021.100654
|
| 16 |
Marisa Couluris, Brent W. Kinder, Ping Xu, Margaret Gross-King, Jeffrey Krischer, Ralph J. Panos. Treatment of Idiopathic Pulmonary Fibrosis with Losartan: A Pilot Project. Lung 2012; 190(5): 523 doi: 10.1007/s00408-012-9410-z
|
| 17 |
Silvia Sookoian, Carlos J. Pirola. Review article: shared disease mechanisms between non‐alcoholic fatty liver disease and metabolic syndrome – translating knowledge from systems biology to the bedside. Alimentary Pharmacology & Therapeutics 2019; 49(5): 516 doi: 10.1111/apt.15163
|
| 18 |
Gustavo Castaño, Cristina Etchart, Silvia Sookoian. Vitamin A toxicity in a physical culturist patient: A case report and review of the literature. Annals of Hepatology 2006; 5(4): 293 doi: 10.1016/S1665-2681(19)31992-1
|
| 19 |
Gustavo O. Castano, Silvia C. Sookoian. Angiotensin II type 1 receptor blockade in early cirrhosis. Journal of Hepatology 2007; 47(3): 426 doi: 10.1016/j.jhep.2007.06.007
|
| 20 |
Ling-Zu Kong, Nisansala Chandimali, Ying-Hao Han, Dong-Ho Lee, Ji-Su Kim, Sun-Uk Kim, Tae-Don Kim, Dong Kee Jeong, Hu-Nan Sun, Dong Sun Lee, Taeho Kwon. Pathogenesis, Early Diagnosis, and Therapeutic Management of Alcoholic Liver Disease. International Journal of Molecular Sciences 2019; 20(11): 2712 doi: 10.3390/ijms20112712
|
| 21 |
Wilma Debernardi-Venon, Silvia Martini, Fiorella Biasi, Barbara Vizio, Angela Termine, Giuseppe Poli, Franco Brunello, Carlo Alessandria, Renato Bonardi, Giorgio Saracco, Mario Rizzetto, Alfredo Marzano. AT1 receptor antagonist Candesartan in selected cirrhotic patients: Effect on portal pressure and liver fibrosis markers. Journal of Hepatology 2007; 46(6): 1026 doi: 10.1016/j.jhep.2007.01.017
|
| 22 |
M. Raimbault, H. Veillon, F. Oberti, P. Calès. Médicaments ayant un effet sur la fibrose hépatique. Journal Africain d'Hépato-Gastroentérologie 2007; 1(3-4): 110 doi: 10.1007/s12157-008-0031-3
|
| 23 |
Lakmie S. Gunarathne, Peter W. Angus, Chandana B. Herath. Blockade of Mas Receptor or Mas-Related G-Protein Coupled Receptor Type D Reduces Portal Pressure in Cirrhotic but Not in Non-cirrhotic Portal Hypertensive Rats. Frontiers in Physiology 2019; 10 doi: 10.3389/fphys.2019.01169
|
| 24 |
Gaeun Kim, Juyoung Kim, Yoo Li Lim, Moon Young Kim, Soon Koo Baik. Renin–angiotensin system inhibitors and fibrosis in chronic liver disease: a systematic review. Hepatology International 2016; 10(5): 819 doi: 10.1007/s12072-016-9705-x
|
| 25 |
Angela Douglass, Karen Wallace, Matthew Koruth, Caroline Barelle, Andrew J. Porter, Matthew C. Wright. Targeting liver myofibroblasts: a novel approach in anti-fibrogenic therapy. Hepatology International 2008; 2(4) doi: 10.1007/s12072-008-9093-y
|
| 26 |
Li Gu, Yahui Zhu, Maiya Lee, Albert Nguyen, Nicolas T. Ryujin, Jian Yu Huang, Shusil K. Pandit, Shadi Chamseddine, Lianchun Xiao, Yehia I. Mohamed, Ahmed O. Kaseb, Michael Karin, Shabnam Shalapour. Angiotensin II receptor inhibition ameliorates liver fibrosis and enhances hepatocellular carcinoma infiltration by effector T cells. Proceedings of the National Academy of Sciences 2023; 120(19) doi: 10.1073/pnas.2300706120
|
| 27 |
Keshvad Hedayatyanfard, Nazgol‐Sadat Haddadi, Seyed Ali Ziai, Hossein Karim, Feizollah Niazi, Ulrike Muscha Steckelings, Behnam Habibi, Ali Modarressi, Ahmad‐Reza Dehpour. The renin‐angiotensin system in cutaneous hypertrophic scar and keloid formation. Experimental Dermatology 2020; 29(9): 902 doi: 10.1111/exd.14154
|
| 28 |
Suchithra Poilil Surendran, Reju George Thomas, Myeong Ju Moon, Rayoung Park, Jae Hyuk Lee, Yong Yeon Jeong. A bilirubin-conjugated chitosan nanotheranostics system as a platform for reactive oxygen species stimuli-responsive hepatic fibrosis therapy. Acta Biomaterialia 2020; 116: 356 doi: 10.1016/j.actbio.2020.09.014
|
| 29 |
Russell Snyder, Thomas Thekkumkara. 13-cis-Retinoic acid specific down-regulation of angiotensin type 1 receptor in rat liver epithelial and aortic smooth muscle cells. Journal of Molecular Endocrinology 2012; 48(2): 99 doi: 10.1530/JME-11-0095
|
| 30 |
M Kamruzzman Munshi, Mohammad N Uddin, Shannon S Glaser. The role of the renin–angiotensin system in liver fibrosis. Experimental Biology and Medicine 2011; 236(5): 557 doi: 10.1258/ebm.2011.010375
|
| 31 |
Moran Elbaz, Nurit Yanay, Shlomit Aga‐Mizrachi, Zivia Brunschwig, Ibaa Kassis, Keren Ettinger, Vivian Barak, Yoram Nevo. Losartan, a therapeutic candidate in congenital muscular dystrophy: Studies in the dy2J/dy2J Mouse. Annals of Neurology 2012; 71(5): 699 doi: 10.1002/ana.22694
|
| 32 |
Hala M. Raslan, Khalda S. Amr, Yasser A. Elhosary, Wafaa M. Ezzat, Nour A. Abdullah, Hassan E. El-Batae. Possible role of angiotensin-converting enzyme polymorphism on progression of hepatic fibrosis in chronic hepatitis C virus infection. Transactions of the Royal Society of Tropical Medicine and Hygiene 2011; 105(7): 396 doi: 10.1016/j.trstmh.2011.03.005
|
| 33 |
Jessica M. Motherwell, Connor P. Dolan, Sergey S. Kanovka, Jorge B. Edwards, Sarah R. Franco, Naveena B. Janakiram, Michael S. Valerio, Stephen M. Goldman, Christopher L. Dearth. Effects of Adjunct Antifibrotic Treatment within a Regenerative Rehabilitation Paradigm for Volumetric Muscle Loss. International Journal of Molecular Sciences 2023; 24(4): 3564 doi: 10.3390/ijms24043564
|
| 34 |
Carlos J. Pirola, Silvia Sookoian. Non‐alcoholic fatty liver disease mediates the effect of obesity on arterial hypertension. Liver International 2023; 43(10): 2167 doi: 10.1111/liv.15643
|
| 35 |
Puneeta Tandon, Juan G. Abraldes, Annalisa Berzigotti, Juan Carlos Garcia-Pagan, Jaime Bosch. Renin–angiotensin–aldosterone inhibitors in the reduction of portal pressure: A systematic review and meta-analysis. Journal of Hepatology 2010; 53(2): 273 doi: 10.1016/j.jhep.2010.03.013
|
| 36 |
Fiona Oakley, Derek A. Mann. Stellate Cells in Health and Disease. 2015; : 251 doi: 10.1016/B978-0-12-800134-9.00015-4
|
| 37 |
J. Heller, B. Appenrodt, M. Schepke, T. Sauerbruch. Varizenblutung bei Patienten mit Leberzirrhose. Der Gastroenterologe 2007; 2(4): 238 doi: 10.1007/s11377-007-0089-2
|
| 38 |
John S Lubel, Chandana B Herath, Louise M Burrell, Peter W Angus. Liver disease and the renin–angiotensin system: Recent discoveries and clinical implications. Journal of Gastroenterology and Hepatology 2008; 23(9): 1327 doi: 10.1111/j.1440-1746.2008.05461.x
|
| 39 |
T. Sauerbruch, J. Trebicka. Pathogenesis and Clinical Practice in Gastroenterology. 2008; 160: 233 doi: 10.1007/978-1-4020-8767-7_22
|
| 40 |
Kristian Aquilina, Catherine Hobbs, Alexander Tucker, Andrew Whitelaw, Marianne Thoresen. Do drugs that block transforming growth factor beta reduce posthaemorrhagic ventricular dilatation in a neonatal rat model?. Acta Paediatrica 2008; 97(9): 1181 doi: 10.1111/j.1651-2227.2008.00903.x
|
| 41 |
George B Goh, Mangesh R Pagadala, Jaividhya Dasarathy, Aynur Unalp‐Arida, Ruth Sargent, Carol Hawkins, Achuthan Sourianarayanane, Amer Khiyami, Lisa Yerian, Rish Pai, Arthur J McCullough, Srinivasan Dasarathy. Renin‐angiotensin system and fibrosis in non‐alcoholic fatty liver disease. Liver International 2015; 35(3): 979 doi: 10.1111/liv.12611
|
| 42 |
Zuo-Wei Ning, Xiao-Ying Luo, Guo-Zhen Wang, Yang Li, Miao-Xia Pan, Ren-Qiang Yang, Xu-Guang Ling, Shan Huang, Xiao-Xin Ma, Si-Yi Jin, Dan Wang, Xu Li. MicroRNA-21 Mediates Angiotensin II-Induced Liver Fibrosis by Activating NLRP3 Inflammasome/IL-1β Axis via Targeting Smad7 and Spry1. Antioxidants & Redox Signaling 2017; 27(1): 1 doi: 10.1089/ars.2016.6669
|
| 43 |
Ghulam Abbas, Marina G Silveira, Keith D Lindor. Hepatic Fibrosis and the Renin-Angiotensin System. American Journal of Therapeutics 2011; 18(6): e202 doi: 10.1097/MJT.0b013e3181df8df5
|
| 44 |
Abd Elkhalek Hamed, Medhat Elsahar, Nadia M. Elwan, Sarah El-Nakeep, Mervat Naguib, Hanan Hamed Soliman, Ashraf Ahmed Aboubakr, Amany AbdelMaqsod, Heba Sedrak, Samir N. Assaad, Reda Elwakil, Gamal Esmat, Samira Salh, Taymour Mostafa, Sherif Mogawer, Sameh Emil Sadek, Maha M. Saber, Hanan Ezelarab, Asem Ashraf Mahmoud, Souad Sultan, Mohamed El Kassas, Ehab Kamal, Naglaa M. ElSayed, Shorouk moussa. Managing diabetes and liver disease association. Arab Journal of Gastroenterology 2018; 19(4): 166 doi: 10.1016/j.ajg.2018.08.003
|
| 45 |
S. Lemoinne, A. Cadoret, N. Bosselut, C. Housset, D. Wendum, D. Thabut. Fibrose hépatique. EMC - Hépatologie 2012; 7(4): 1 doi: 10.1016/S1155-1976(12)59788-3
|
| 46 |
Antony Sameh Mansour. Autoregulation: mediators and renin–angiotensin system in diseases and treatments. Future Journal of Pharmaceutical Sciences 2023; 9(1) doi: 10.1186/s43094-023-00482-4
|
| 47 |
Ahmed Sadek, Ahmed M. Abd El Hady, Hammam Olfat, Afaf A. Abd El Hady, Wafaa Wafy, Moushira Zaki, Eman R. Youness. Effect of ozone gas on viral kinetics and liver histopathology in hepatitis C patients. Journal of Complementary and Integrative Medicine 2024; 21(1): 131 doi: 10.1515/jcim-2023-0239
|
| 48 |
Moon Young Kim, Mee Yon Cho, Soon Koo Baik, Phil Ho Jeong, Ki Tae Suk, Yoon Ok Jang, Chang Jin Yea, Jae Woo Kim, Hyun Soo Kim, Sang Ok Kwon, Byung Su Yoo, Jang Young Kim, Min Seob Eom, Seung Hwan Cha, Sei Jin Chang. Beneficial effects of candesartan, an angiotensin‐blocking agent, on compensated alcoholic liver fibrosis ‐ A randomized open‐label controlled study. Liver International 2012; 32(6): 977 doi: 10.1111/j.1478-3231.2012.02774.x
|
| 49 |
Kwang Yong Shim, Young Woo Eom, Moon Young Kim, Seong Hee Kang, Soon Koo Baik. Role of the renin-angiotensin system in hepatic fibrosis and portal hypertension. The Korean Journal of Internal Medicine 2018; 33(3): 453 doi: 10.3904/kjim.2017.317
|
| 50 |
Jordi Colmenero, Ramón Bataller, Pau Sancho-Bru, Marlene Domínguez, Montserrat Moreno, Xavier Forns, Miquel Bruguera, Vicente Arroyo, David A. Brenner, Pere Ginès. Effects of losartan on hepatic expression of nonphagocytic NADPH oxidase and fibrogenic genes in patients with chronic hepatitis C. American Journal of Physiology-Gastrointestinal and Liver Physiology 2009; 297(4): G726 doi: 10.1152/ajpgi.00162.2009
|
| 51 |
Anureet K. Shah, Sushma Yadav, Hoda Yeganehjoo. The Renin Angiotensin System in Cancer, Lung, Liver and Infectious Diseases. Advances in Biochemistry in Health and Disease 2023; 25: 3 doi: 10.1007/978-3-031-23621-1_1
|
| 52 |
Michaela Granzow, Robert Schierwagen, Sabine Klein, Benita Kowallick, Sebastian Huss, Markus Linhart, Irela G. Reza Mazar, Jan Görtzen, Annabelle Vogt, Frank A. Schildberg, Maria A. Gonzalez-Carmona, Alexandra Wojtalla, Benjamin Krämer, Jacob Nattermann, Sören V. Siegmund, Nikos Werner, Dieter O. Fürst, Wim Laleman, Percy Knolle, Vijay H. Shah, Tilman Sauerbruch, Jonel Trebicka. Angiotensin-II type 1 receptor-mediated Janus kinase 2 activation induces liver fibrosis. Hepatology 2014; 60(1): 334 doi: 10.1002/hep.27117
|
| 53 |
Silvia Sookoian, Carlos J Pirola. Repurposing drugs to target nonalcoholic steatohepatitis. World Journal of Gastroenterology 2019; 25(15): 1783-1796 doi: 10.3748/wjg.v25.i15.1783
|
| 54 |
Yating Li, Hong Xu, Wenrui Wu, Jianzhong Ye, Daiqiong Fang, Ding Shi, Lanjuan Li. Clinical application of angiotensin receptor blockers in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis. Oncotarget 2018; 9(35): 24155 doi: 10.18632/oncotarget.23816
|
| 55 |
P. Calès, J. Boursier, J. Chaigneau, F. Oberti, M.-C. Rousselet. Treatment of liver fibrosis: Clinical aspects. Gastroentérologie Clinique et Biologique 2009; 33(10-11): 958 doi: 10.1016/j.gcb.2009.07.020
|
| 56 |
Paul Manka, Amos Zeller, Wing-Kin Syn. Fibrosis in Chronic Liver Disease: An Update on Diagnostic and Treatment Modalities. Drugs 2019; 79(9): 903 doi: 10.1007/s40265-019-01126-9
|
| 57 |
Abd Elkhalek Hamed. The association between diabetes and liver disease: The need for a consensus. Arab Journal of Gastroenterology 2014; 15(3-4): 166 doi: 10.1016/j.ajg.2014.09.002
|
| 58 |
Sarkawt Hamad, Ismail Maulood. Hemodynamic and renal effects of bosentan and losartan in 2k1c hypertensive rats.. Journal of Zankoy Sulaimani - Part A 2016; 18(2): 63 doi: 10.17656/jzs.10504
|
| 59 |
Qianqian Zhu, Na Li, Fang Li, Zhihua Zhou, Qunying Han, Yi Lv, Jiao Sang, Zhengwen Liu. Therapeutic effect of renin angiotensin system inhibitors on liver fibrosis. Journal of the Renin-Angiotensin-Aldosterone System 2016; 17(1) doi: 10.1177/1470320316628717
|